Edouard L. Fu

Why did observational studies find ⬆️survival for late dialysis initiation, whereas the IDEAL RCT found no difference? Was it confounding, the usual culprit we point to? No! Our new paper @bmj_latest addresses this and much more! #epitwitter #nephtwitter bmj.com/content/375/bm…

Care Processes and Clinical Responses to Newly Detected Albuminuria: The Stockholm Creatinine Measurements (SCREAM) Project bit.ly/44KGFu7 (OPEN ACCESS) @AntoineCreon @meg21212 @FuEdouard @jjcarrero1

Research methods and reporting: How to align eligibility and treatment assignment at time zero when emulating a target trial. This article provides methodological guidance when emulating a target trial with longitudinal observational data @FuEdouard bmj.com/content/392/bm…

Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial bmj.com/content/392/bm… via @FuEdouard et al

While target trial emulation cannot remove bias from inadequate data, it eliminates common biases induced by an incorrect design. This article provides methodological guidance when emulating a target trial with longitudinal observational data @FuEdouard bmj.com/content/392/bm…

Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial bmj.com/content/392/bm… via @FuEdouard et al @RWJE_BA

🔹 Publish in top journals & shape global guidelines 🔹 Supportive, collaborative team + strong mentorship 👉 PhD 1 - MD background: lumc.nl/en/about-lumc/… 👉 PhD 2 - Data science/(Bio)statistics/Epidemiology background: lumc.nl/en/about-lumc/…

📢 We’re hiring 2 PhD candidates @LUMC! Help transform patient care by personalizing treatments for cardio‑kidney‑metabolic diseases using big data & causal inference. We offer 🔹 Data from >20M patients 🔹 Cutting‑edge causal & ML methods 🔹 Collaborate w/ Karolinska & UCSF

Trends in Major Cardiovascular Events and Bleeding Among Patients With Advanced CKD: A Nationwide Swedish Study @meg21212 @FuEdouard @karin_modig @jjcarrero1 bit.ly/4osse52 #OpenAccess

1/9🚨 Changing one formula could make 38% more people “have CKD” overnight. That’s what happens if we replace the CKD-EPI equation with EKFC in a European health system. 👉 Our @NDTsocial paper shorturl.at/T5Dui #CKD #GFR #nephtwitter @jjcarrero1 @FuEdouard @PStoneOftheYear

Discordances Between Creatinine- and Cystatin C–Based Estimated GFR and Adverse Clinical Outcomes in Routine Clinical Practice bit.ly/4491HQp #OpenAccess @jjcarrero1 @FuEdouard @Shoshana_Ballew @CarlElinder @LAInker @ASLtufts @meg21212

Finally, a good modern book on causality for ML: causalai-book.net by @eliasbareinboim. This looks like a worthy successor to the ground breaking book by @yudapearl which I read in grad school. (h/t @JoshuaSafyan for the ref).

🧵1/9 Could we improve kidney care by rethinking who gets referred to a nephrologist? Our latest study from the SCREAM cohort suggests: yes — if we base it on predicted risk rather than fixed eGFR/ACR cutoffs. 📄 Caldinelli et al, 2025, @NDTsocial 🔗shorturl.at/0CzNq

Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular Disease bit.ly/Mazhar25OI #OpenAccess #VisualAbstract @FuEdouard @VladoPerkovic @KatherineTuttl8 @jjcarrero1

#GDMT has now arrived for #HFpEF #SGLT2i (class I) and #nsMRA (class IIa) recommendations in initial global guidelines jstage.jst.go.jp/article/circj/… #HeartFailure2025

The 24th Sounds and Science concert features: 🎼 Mozart’s Marriage of Figaro & Violin Sonata 🎼 Dvořák’s Sonatina & Slavonic Dance No. 2 🎙️ With talks on kidney immunology & the composers' lives by @PRomagnani Hosted by nephrologists @EllerKathrin & @RainerOberbauer

🎶 Attending #ERA2025 in Vienna? Don't miss Music & Kidney — a unique evening where classical music meets nephrology! 🗓️ Wednesday June 4 | 🕘 21:00 | 📍 Sofiensäle 🔗soundsandscience.com/index.php?id=1… @ERAkidney @jjcarrero1 #MusicAndMedicine #Nephrology #ViennaEvents

*30 years* after the start of the RALES trial the targeting of the MR axis remains one of the hottest areas of drug development across cardio-kidney-metabolism Expected read-outs in '25: #ACHIEVE sMRA in ESKD #CONFIDENCE Combo nsMRA+SGLT2i in CKD #SPIRITHF sMRA in HFmrEF/HFpEF

🔥 #CONFIDENCE closed out & selected as LBCT to headline #ERA25, led by #ProfRajivAgarwal Largest RCT to test combination #SGLT2i empagliflozin & #nsMRA finerenone Will 1+1 = 2? Baseline: academic.oup.com/ndt/advance-ar… Design: academic.oup.com/ndt/article/38… See you in Vienna 🇦🇹 @ERAkidney

Causal inference in observational studies can be tricky. We discuss key methodological considerations from a recent study in JASN @asnpublications. With @FuEdouard and @jjcarrero1. Read it here: tinyurl.com/rwzu37xu

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study bit.ly/3CFBHmW #OpenAccess @ELambourg @FuEdouard @C_H_Grant @johnrpetrie @SamiraBell76 #VisualAbstract #CKD